After MindMed’s up-listing, the company has been facing a lot of instability and turbulence in the past few months and years. It has been struggling to establish stability in a sector that is still struggling.
Get the latest news on psychedelic stocks Cybin, Numinus, MindMed, ATAI, Mindset, Braxia, Tryp, Irwin Naturals, and Revive
The psychedelic renaissance hits a rough patch as major companies look to tighten their belts or face total collapse. What’s happening with Psychedelic Stocks?
Despite an overarching shared thesis, the four psychedelics ETFs differ in philosophy, strategy, execution, and size. This leads them to having different sized stakes companies, and their long-term success will vary.
Our resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.
No one is responsible for your financial future, other than yourself, so be responsible with your money.
Introducing the Benzinga Psychedelics Capital Conference on April 19 in Miami Beach,
Our resident Psychedelic Investor James Hallifax looks at the pros and cons of this Canadian-based company developing DMT for therapeutic use.
Elemental Advisors Inc. CEO Tim Collins paints a picture of the past, present, and future of the psychedelics market in this guest blog.
Our resident Psychedelic Investor explores one of the biggest questions on minds of those investing in psychedelic stocks.
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.